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Use of an Evidence‐Based
Evidence Based Guideline for Management of Side Effects from
Long‐Acting
Long Acting Reversible Contraceptives: A Quality Improvement Report
Abstract

Introduction
Many health care providers believe that women who initiate long‐acting reversible contraceptives (LARC)
discontinue the method because of side effects too soon for the method to be economical. The purpose
of this quality improvement project was to implement and evaluate an evidence‐based telephone triage
nursing guideline for management of side effects of LARC with an ultimate goal of reducing the number
of early discontinuations.

Process
A telephone triage guideline was adapted from the Contraceptive Choice Project's Clinician Call Back
System, supplemented with evidence‐based resources, and approved by clinicians at 2 community
women's health and midwifery offices. Baseline retrospective data were collected on all women over the
age of 18 who had LARC inserted at the 2 sites in the year prior to guideline implementation and in the 3
months after implementation. Rates of LARC removal at or before 3 months postinsertion, before and
after guideline implementation, were evaluated.

Outcomes
Approximately 1 in 5 women called for help managing LARC side effects. Of the callers, 3 of 32 (9.4%)
women receiving standard care discontinued their LARC prior to 3 months, whereas 0 of 24 women who
were triaged using the guideline discontinued their LARC prior to 3 months (P = .12). Cramping, bleeding,
and malposition or expulsion were the most common concerns and reasons for discontinuation.

Discussion
Fewer women than anticipated called to report side effects, and even fewer chose to discontinue their
LARC early. There were fewer discontinuations with guideline use, but this was not a statistically
significant difference. Most women did not discontinue their LARC early for any reason, including side
effects.
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Précis: Few women experience LARC adverse effects; very few discontinue early. Use
of the guideline is associated with a trend in decreased early discontinuation.
Structured Abstract
Introduction
Long-acting reversible contraceptives (LARC) are safe, highly effective methods for
pregnancy prevention that are cost effective if used for an extended duration. Many
healthcare providers believe that women who initiate LARC do not tolerate the common
side effects and choose to remove them too soon for them to be economical. The purpose
of this pilot study was to develop, implement, and evaluate an evidence-based telephone
triage nursing guideline to manage side effects of LARC to reduce the number of LARC
users who discontinue their method early.
Methods
Baseline retrospective data was collected on a convenience sample of all women over age
18 who had LARC inserted in the prior year at two community women’s health and
midwifery offices. The guideline was then implemented and data collected for three
months post-insertion on a convenience sample of all women over 18 who had LARC
inserted after guideline implementation. Chi-square testing and Kaplan-Meier survival
analysis were used to evaluate the efficacy of the guideline on rates of LARC removal at
or before 3 months post-insertion.
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Results
In both cohorts, approximately 1 in 5 women called for help managing side effects. Of
the women who called, 9.4% of women receiving standard care discontinued their LARC
prior to 3 months, while zero women who were triaged using the guideline discontinued
their LARC prior to 3 months (p = 0.12).
Discussion
Fewer women called to report side effects than anticipated, and even fewer chose to
discontinue their LARC early. The small numbers of women calling and discontinuing
lowered statistical power, but there was a trend toward fewer early discontinuations with
use of the telephone triage guideline compared to use of non-standardized management
strategies.
Keywords: Contraception/Family Planning, Gynecology, Pain Management,
Preventative Health Care, Sexual Health, Long-Acting Reversible Contraception,
Intrauterine Devices, Adverse Effects
Quick Points:
•

LARC are an efficacious and cost-effective option for women wishing to avoid
pregnancy for an extended duration.

•

Very few women discontinue their LARC methods early for any reason.

•

Contrary to popular provider perception, most women continue their LARC
beyond 3 months, when side effects are most troublesome.

•

Use of a guideline for managing the adverse effects of LARC may decrease the
rate of early discontinuation of the devices.
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Introduction & Background
Long-acting, reversible contraceptives (LARC) are a popular topic due to their
proven efficacy at preventing unplanned pregnancy. LARC include both levonorgestrel
intrauterine devices (IUDs) and copper IUDs as well as etonorgestrel subdermal implants
(SDIs). A single LARC can be used continuously for up to 3-12 years and are more than
99% effective with both perfect and typical use. Once inserted, they are effective almost
immediately and continue to work until expiration without any further effort by the user.1
At the time of insertion, LARC methods are more expensive than other contraceptives,
but if used for an extended duration, their average cost is comparable to or less than the
other methods.2
Although LARC are recommended by several major medical organizations as
first-line contraceptives for all women wishing to avoid pregnancy,3,4,5 LARC remain
underutilized in the United States. While low LARC usage is multifactorial, part of the
problem is provider ambivalence toward LARC. This is due to the perception that many
women discontinue their LARC due to side effects too early for the method to be a costeffective choice.6 Early removal due to side effects, especially cramping and bleeding, is
documented in the literature,7,8,9,10,11 although the definition of “early removal” is not
standardized. However, no study has evaluated the methods for managing LARC side
effects with the goal of minimizing discontinuation due to LARC side effects. The
purposes of this study included evaluation of the characteristics of women utilizing
LARC methods, their complaints and reasons for early discontinuation, and whether rates
of early discontinuation improved after implementation of a standardized, evidence-based
telephone triage guideline for management of LARC side effects.
The Interaction Model of Client-Health Behavior was used to design this study.
Central concepts of the model include client singularity, client-professional interaction,
and health outcomes.12 Client singularity was utilized to identify the pertinent
demographics and individual variables that might impact the outcomes of interest, as well
as factor in the individual variables outside of provider control that must be considered
when applying conclusions. Client-professional interaction served as the basis for using a
guideline to assist nurses in managing the side effects experienced by the LARC user.
Health outcomes were the measurable results of the client health behavior; in this study,
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the primary outcome was whether the women removed their LARC prior to 3 months’
use.
Methods
This pilot study utilized a two cohort, time-series design with analysis of
retrospective electronic medical record data from LARC users before and after guideline
implementation. The study was conducted at two institutionally-affiliated women’s health
and midwifery clinics in an urban setting. This study received exempt status from the St
John Fisher College IRB prior to initiation of the study procedures.
A convenience sample of LARC users was identified from an insertion log kept in
the regular course of practice at the two clinics. Because data was collected
retrospectively and de-identified prior to analysis, consent was not required, and so data
was collected from all adult women (age ≥18 years) who had LARC inserted at the clinic
during the dates specified by the cohort. The first cohort included women who had any
type of LARC (hormonal IUD, copper IUD, or SDI) placed between March 1, 2016 February 28, 2017. A computer algorithm was used to pull insertion, post-insertion visit,
phone call, or procedure notes for each woman. Notes were de-identified and then the
following data was manually abstracted: age, gravidity & parity, postpartum status
(having given birth within 3 months prior to insertion date), LARC type, number of
phone calls, and complaint reported in the phone call. The primary outcome, whether
each woman discontinued her LARC prior to 3 months’ use and if so, for what reason,
was also abstracted from these notes. A separate algorithm was used to identify race and
insurance type for each woman. Data were organized by a randomly assigned subject ID
and compiled into an Excel spreadsheet.
An evidence-based guideline for managing LARC side effects using telephone
triage was developed by the researcher (JJ). The guideline includes a flowchart for
triaging patient calls related to LARC issues, a list of signs of clinical urgency requiring
immediate care, and specific guidelines with rationale for management of common
LARC side effects including dysmenorrhea, menorrhagia & metrorrhagia, increased
vaginal discharge, hormonal side effects, dyspareunia, and pain at insertion site. Prior to
implementation, the guideline was reviewed by clinical experts and approved by lead
providers at the clinical sites. The guideline was reviewed with triage RNs at both clinical
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sites over three separate days prior to implementation. The guideline was distributed to
clinical providers via email prior to implementation. All providers and RNs were
encouraged to contact the researcher with questions or concerns about the guideline at
any time. The guideline was implemented on June 1, 2017.
The second cohort included women who had any type of LARC placed between
June 1 and September 1, during guideline implementation. A computer algorithm was
used to pull insertion, post-insertion visit, phone call, or procedure notes for each woman
and then the same variables were abstracted and recorded as was done in Cohort 1. Data
was aggregated and reviewed in Excel, and statistical analyses were completed using
SPSS. Chi-square, t-testing, and Kaplan-Meier life table analysis were used for
comparisons.
Results
A total of 293 LARC users were included in the study. One subject had been
excluded due to missing data. Due to the shorter available data collection period, there
were more women in Cohort 1 (n=183) than Cohort 2 (n=110). Comparative data for all
LARC users is displayed in Table 1. Chi square tests showed significant differences
between cohorts, including race, use of public insurance, postpartum status, and type of
LARC (p<0.001). The percent of women who called to report LARC side effects was not
significantly different between Cohort 1 and Cohort 2 (p=0.36).
Approximately 1 in 5 women called with a complaint of LARC side effects.
Descriptive statistics for callers can be seen in Table 2. Of these women, there were no
statistically significant demographic or descriptive differences between Cohort 1 and
Cohort 2, although power was limited due to small sample size. As shown in Table 3, the
most common complaints of callers were bleeding (55.6%) and cramping (32.1%). Only
23 women (7.8%) had their LARC removed during follow-up, and only 11 (3.9%)
discontinued their LARC within 3 months of insertion. The reasons for early
discontinuation are listed in Table 4. Of note, 5 of the 23 women discontinued their
LARC due to expulsion or malposition (included in the “other” category) and zero
discontinued due to cramping.
Two-tailed Chi-square (with T-tests for the continuous variable, age) was used to
determine whether variables were associated with the primary outcome (whether LARC
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users in each cohort had discontinued their LARC prior to 3 months post-insertion).
Results of these tests for all LARC users and for the Callers subset can be viewed on
Table 5. No statistically significant association was found between any variables and
discontinuation except for cohort designation (p=0.047) among all LARC users. Among
the callers subset, no statistically significant association was found between any variables
and discontinuation. Kaplan-Meier survival analysis was used to analyze the pattern of
discontinuation between cohorts among the caller subset, as seen in Figure 1. A trend
toward less discontinuation in Cohort 2 was noted, although it did not reach statistically
significance (Log Rank p= 0.13). Multivariable Cox regressions in the Caller subgroup,
intended to adjust for differences between the two cohorts (i.e., assess for possible
confounding), could not be performed due to insufficient sample size.
Discussion
Although the study was limited by sample size and duration of follow-up, the
results provide additional information on the relationships between side effects, duration
of LARC use, and removal. These conclusions largely support the existing evidence but
also provide additional insight into the LARC user and provider experience.
A common belief is that most women experience LARC side effects after
insertion. While this study could not determine how many women experienced side
effects, it did show that approximately 1 in 5 women called for assistance in managing
their side effects. If any of the other 80% who did not call had adverse effects, it is
assumed that they were tolerable without medical management or could wait until a
scheduled follow-up appointment at 6-8 weeks post-insertion.
Providers commonly perceive that “many” women get their LARC out early due
to side effects,6 although this perception has been challenged in the literature.7,8,9,10,11 In
this study, only 8% of women discontinued their LARC early, and even fewer (5.5%)
discontinued within three months. This suggests that most women do continue their
LARC past the first three months, when side effects are most troublesome, contrary to
provider perception. It is likely that provider perception is influenced by availability bias,
providing more reason for evaluation of real patient outcomes to counteract this
perception.
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The rate of calls for LARC complaints was not significantly different between
cohorts; however, 3 callers discontinued their LARC in Cohort 1, versus 0 in Cohort 2.
While not statistically significant and limited by the number of women who called, there
is clinical value in decreasing early LARC removal from 3 to 0. Viewed a different way,
100% of women in Cohort 2 who were counseled using the guideline decided to continue
their LARC past 3 months, which provides some evidence to support further evaluation
and possible dissemination of the guideline.
Strengths of this study include a diverse sample, complete data, and precise
descriptive data due to sampling technique. The conclusions support existing evidence
and provide evidence supporting further evaluation of the triage guideline. In addition,
the conclusion that only a small proportion of women choose to remove LARC early for
any reason, but especially due to side effects, refutes the belief that, for many women,
LARC are not a cost-effective option.
This study had limitations. Statistical power was restricted by the small sample
size of the subset of callers. As previously discussed, multivariable regression to adjust
for between-cohort differences could not be done on the Caller subgroup. Although none
of the differences had univariate associations with outcome, the numbers were small. In
addition, follow-up data was limited by the short duration of follow-up, dictated by the
parameters of the pilot study. Since women often presented for routine follow-up
appointments after LARC placement without calling telephone triage, some opportunities
for use of the guideline were lost. Revision and evaluation of the guideline for use in pre& post-insertion and follow-up counseling could provide insight into the efficacy of the
guideline in these circumstances. Lastly, political and economic factors may have
influenced LARC continuation.
Further research into the efficacy of the guideline is warranted. Future studies can
provide larger samples in conjunction with longer follow-up. Qualitative data regarding
patient satisfaction and experience with side effect management is important to ensuring
that patient autonomy is not lost in the pursuit of high contraceptive efficacy and costeffectiveness.
Conclusion
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The trend toward decreased discontinuation of LARC with use of the guideline
(although not statistically significant) and the absence of known risks to utilizing the
guideline supports dissemination and use of the guideline, with continued evaluation, in
women’s health, primary care, and pediatric practices to improve LARC use. Use of the
guideline could reduce health care costs by reducing patient visits for management of
side effects and more effectively utilizing the nursing scope of practice. LARC have the
potential to improve the lives of women if the healthcare system is adequately able to
support the LARC users for as long as they wish to continue the method.
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Table 1: Descriptive Statistics for All LARC Users by Cohort (n = 293)
Demographic
Cohort 1
Cohort 2
p-value
Characteristics
183
110
Total n
30.2 (SD 6.2)
29.8 (SD
0.78
Mean Age (years)
7.8)
<0.001
Race
Black
24 (13.1%) 35 (31.8%)
White
141 (77.0%) 59 (53.6%)
Other
18 (9.8%) 16 (14.5%)
a
63 (34.0%) 62 (56.4%)
<0.001
Public Insurance
28 (15.3%) 23 (20.9%)
0.22
Nulliparity
91 (49.7%) 33 (30.0%)
<0.001
Postpartum
32 (17.5%) 24 (21.8%)
0.36
# LARC Users Called
<0.001
Type of LARC
Nexplanon
27 (14.8%) 44 (40.0%)
Hormonal IUD
102 (55.7%) 51 (46.4%)
Copper IUD
51 (27.9%) 13 (11.8%)
Age evaluated with t-testing, and all others with chi-square
a
Medicaid
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Table 2: Descriptive Statistics for Callers Subset by Cohort (n = 56)
Demographic Variables
Cohort 1
Cohort 2
p-value
32
24
Total n
28.4 (SD 5.6) 29.8 (SD 7.2)
0.43
Mean Age (years)
0.12
Race
Black
5 (15.6%)
7 (29.2%)
White
23 (71.9%)
17 (70.8%)
Other
4 (12.5%)
0 (0%)
12 (35.7%)
12 (50.0%)
0.35
Public Insurancea
8 (25.0%)
5 (20.8%)
0.72
Nulliparity
11 (34.4%)
4 (16.7%)
0.14
Postpartum
0.22
Type of LARC
Nexplanon
4 (40.0%)
6 (25.0%)
Hormonal IUD
15 (40.6%)
13 (27.8%)
Copper IUD
13 (46.9%)
5 (54.2%)
Age evaluated with t-testing, and all others with chi-square
a
Medicaid
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Table 3: Reported LARC Side Effects of Callers (n = 56)
Side Effect Reported
n (%)
31 (55.4%)
Bleeding
18 (32.1%)
Cramping
8 (14.3%)
Other
7 (12.5%)
Vaginitis
6 (10.7%)
Hormonal
2 (3.6%)
Dyspareunia
1 (1.8%)
Pain at Insertion Site
Some callers reported multiple side effects, so total percentage >100

13
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Table 4: Reasons for Early LARC Discontinuation (n = 23)
Complaint
Other
Bleeding
Hormonal
Desire Conception
Vaginitis

n (%)
8 (34.8%)
5 (21.7%)
5 (21.7%)
4 (17.4%)
1 (4.3%)

14
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Table 5: Analysis of Associations Between Variables and Early Discontinuation
ALL LARC USERS
Variables
Discontinued <3mos
Continued at 3 mos
p-value
31.3 years (SD 8.3)
29.9 years (SD 6.8)
0.51
Age
0.74
Race
White
7 (3.5%)
193 (96.5%)
Black/Other
4 (4.3%)
89 (95.7%)
0.67
Insurance
a
Public Insurance
4 (3.2%)
121 (96.8%)
Other Insurance
7 (4.2%)
161 (95.8%)
0.38
Parity
Nulliparous
3 (5.9%)
48 (94.1%)
Parous
8 (3.3%)
234 (96.7%)
0.30
Postpartum
Yes
3 (2.4%)
121 (97.6%)
No
8 (4.7%)
161 (95.3%)
0.24
LARC Type
Copper IUD
4 (6.3%)
60 (93.7%)
Hormonal IUD or
7 (3.1%)
222 (96.9%)
SDI
0.05
Cohort
1
10 (5.5%)
173 (94.5%)
2
1 (0.9%)
109 (99.1%)
CALLERS
Variables
Discontinued <3mos
Continued
p-value
29 years (SD 8.2)
29 years (SD 6.3)
0.99
Age
0.26
Race
White
3 (7.5%)
37 (92.5%)
Black/Other
0 (0%)
16 (100%)
0.12
Insurance
a
Public Insurance
0 (0.0%)
24 (100%)
Other Insurance
3 (9.4%)
29 (90.6%)
0.67
Nulliparity
1 (7.7%)
12 (92.3%)
2 (4.7%)
41 (95.3%)
0.28
Postpartum
0 (0%)
15 (100%)
3 (7.3%)
38 (92.7%)
0.96
LARC Type
Copper IUD
1 (5.6%)
17 (94.4%)
Hormonal IUD or
2 (5.3%)
36 (94.7%)
SDI
0.12
Cohort
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2

3 (9.4%)
0 (0%)
a

16
29 (90.6%)
24 100%)

Medicaid
Age evaluated with t-testing, and all others with chi-square or Fisher’s exact test

JACOBSON LARC DNP PROJECT MANUSCRIPT
Figure 1: Kaplan-Meier Survival Analysis of Discontinuation of Callers Over Time in
Days

Log-Rank Test: p = 0.127
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Guideline for Managing LARC Side Effects
Adapted with permission from the Contraceptive Choice Project:
Clinician Call-back System1 and IUD & Implant FAQs2,3

Goal: to effectively manage side effects of long-acting reversible contraceptives
(LARC) primarily using telephone triage while promoting patient autonomy.

LARC: Long-acting reversible contraceptives, including the copper IUD (Paragard),
hormonal IUDs (Mirena, Liletta, Skyla), and hormonal implant (Nexplanon)
This guideline is intended to guide clinical practice in relevant patient care
scenarios. It is not a substitute for clinical judgment.
Table of Contents

Patient Call Flowchart
Signs of Clinical Urgency
Resources
Management of LARC Side Effects
References

p.2
p.3
p.3
p.4-6
p.7
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Patient Call Flowchart
• All patient calls regarding existing LARC to be forwarded to Triage RN
o Patient is requesting removal of LARC
 Due to desire for pregnancy?
• Schedule appointment
 Due to expiration of device (confirmed)?
• Determine whether new LARC is desired
• Schedule appointment
 Due to complaint of side effects?
• See below: complaints of side effects
o Patient has complaint of side effects from LARC
 Is complaint is a sign of clinical urgency?
• Consult with on-site provider for next step (ED, stat
visit)
 Is this the first cycle in which patient is reporting side effects of
LARC?
• See guideline for specific side effect management
 Has the patient tried recommended side effect management
strategies?
• If multiple strategies have been unsuccessful for 1 cycle,
assess whether patient is amenable to continuing
strategies for longer.
o If patient insists on removal, schedule removal
 Further discussion of management &
options to be done at removal
appointment by provider
 Is patient too emotional to be triaged by telephone?
• Inform patient that she can schedule appointment to
further discuss her concerns with provider

JACOBSON LARC DNP PROJECT MANUSCRIPT

Signs of Clinical Urgency
• Currently hospitalized with method-related problem
• Excessive vaginal bleeding (saturating >1 pad per hour)
• Fever within 3 weeks of IUD or implant insertion
• Severe redness, swelling, or drainage at implant insertion site
• Severe pelvic pain (patient cannot get out of bed or move)
Consult with provider to refer to ED or make STAT same-day
appointment4,5,6

20
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Management of Complaints with IUDs & Contraceptive Implants

Complaint

Cramping after
insertion or
with menses
(dysmenorrhea)

Management Strategy

Cramping is usually worst in the
first 3 months after IUD insertion
and each month will usually
subside by day 3 of the menstrual
cycle.
1. Heat and rest, as well as
exercise, may help relieve
cramping6,8

2. Take low-dose ibuprofen or
naproxen sodium to help
with the cramping2,6,8

1. Reassure patient that bleeding is
often irregular for first 3-6 months
of use but improves/stabilizes over
time with IUD and implants.
Hormonal IUDS and implants often
result in amenorrhea over time 4,6,8.

2. Over-the-counter (RN to consult
with provider before
recommending):
• Rule out contraindications
to NSAID use
Long, heavy, or
• Start regimen at onset of
irregular
bleeding
menses
(menorrhagia or
• Ibuprofen 600mg tab TID x
metorrhagia)
5-7 days
OR
• Naproxen sodium 220mg
tab 2 tabs BID x 5-7
days2,3,4,6,7,8
If unsuccessful x1 cycle:

3. Rx (forward request to provider)
one of the following:
• Naproxen sodium 500mg
tab 1 tab PO BID x 5-7 days

Rationale
Dysmenorrhea is worst for the first
few cycles after IUD insertion,
especially with the Copper IUD2,6
Cramping is an uncommon
complaint for implant users but
may occur as their cycles adapt to
the continuous hormone level4,7.

Mild to moderate dysmenorrhea
can be managed with a 3-day
course of NSAID therapy2,6.

Patients with persistent
dysmenorrhea or new-onset
dysmenorrhea >6 months after
insertion should be evaluated for
pelvic inflammatory disease,
ectopic pregnancy, and IUD
malposition6
Irregular bleeding with hormonal
contraception is considered to be a
result of the thick endometrium
thinning and developing a dense
but fragile capillary network that
are prone to incidental bleeding
over the first 3-6 months after
insertion2,4,7,8

Reassurance is the primary
management strategy as symptoms
generally resolve on their own
within this time4,6,7
NSAIDs and doxycycline act as
prostaglandin synthetase inhibitor
to restrict pain and bleeding.
Estrogen in COCs can stabilize the
uterine lining to reduce
bleeding2,3,6,7,8

Contraindications to NSAID use
include known NSAID allergy, renal
disease or impairment, history of
gastric ulcers, and concurrent
corticosteroid or anticoagulant use.
Patient history should be carefully
reviewed by provider before high-
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Estrogen supplementation
o Conjugated estrogen
1.25mg 1 tab PO
daily x 7-14 days
o Micronized estradiol
2mg tab PO daily x
7-14 days
o Transdermal
estrogen patch
0.1mg for 7-14 days
Mefenamic acid 500mg tab
BID x 5-7 days
Transexamic acid 500mg
tab BID x 5-7 days
Doxycycline 100mg tab 1
tab PO BID x 7 days2,3,4,6,7,8

Clear or milky vaginal discharge is
normal (leukorrhea).

Increased
vaginal
discharge

Hormonal Side
Effects: Excess
hair growth

IUD and implants provide no
protection against sexually
transmitted infections and a barrier
method, such as condoms, should
be used when there is risk of STI
transmission2,3,6,7,8

If discharge is malodorous,
discolored, or accompanied by
itching, pain, nausea/vomiting, new
onset bleeding, etc, schedule
appointment for screening for
vaginal infection/STI3,6,7,8

These are reported but uncommon
side effects of the hormonal IUDs,
more common with implants, and
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dose NSAID regiment is
recommended9

If irregular bleeding persists
despite management strategies or
patient refuses strategies, an
appointment for removal should be
scheduled to initiate a different
contraceptive method1,4
New or worsening bleeding after
the first 6 months of LARC use
warrants further evaluation for
other causes4,7,8

Leukorrhea is a normal response to
increased progesterone levels with
hormonal contraception7,8
Changes in vaginal flora and pH are
common with IUDs, especially with
concurrent irregular bleeding.
Decreases in lactobacilli and
increases in anaerobic bacteria
commonly result in benign but
bothersome changes in vaginal
discharge9

Triage for signs of infection and
schedule appointment for screening
if vaginal or uterine infection is
suspected. Infections >3 weeks
after IUD insertion date are usually
vaginal and related to STI risk, BV,
or candidiasis6,8.

Risk of PID is elevated only for the
first 3 weeks after IUD insertion.
Oral antibiotics are appropriate for
mild to moderate PID, with
reassessment after 48-72 hours. If
no clinical improvement is seen,
IUD should be removed and sent for
culture and an alternate form of
contraception should be initiated6
The hormonal IUDs may have
systemic hormonal effects such as
hirsutism and acne due to
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Weight gain
Headache
Mood changes
Breast
tenderness
Acne

Partner
Discomfort
During Sex with
IUD

Pain at Implant
Insertion Site

usually resolve as hormone levels
stabilize and the patient’s body
accommodates to the new normal.
Manage symptomatically. Few
patients discontinue use due to
these symptoms2,4,6,8

Educate patient on how to check for
strings and instruct to tuck them
around cervix for comfort or can
come in to have strings
trimmed2,6,7,8
1. Reassurance that low-level
pain or discomfort is
normal for several days
after insertion in absence of
other symptoms4,7
2. Cool compresses, 20
minutes on & off for 2-3
cycles may relieve
discomfort3
3. Once daily low-dose
ibuprofen or naproxen can
be recommended in the
absence of
contraindications3,4,7

References
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decreased androgen suppression in
the absence of exogenous estrogen
present with prior method6,8
Weight gain is usually minimal and
can be mitigated with lifestyle
changes6

Headache, mood changes, breast
tenderness can result from
intolerance of hormones but
frequently resolve after 3-6 months
of use6,8
IUD string length should be
approximately 3-4cm from the os.
Strings that are too short or too
long may cause discomfort for the
partner during penetration6

Pain accompanied by fever,
discharge at the insertion site,
and/or significant swelling and
erythema suggests infection or
rejection and should be evaluated
by a provider in the office4
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